BioCentury | May 28, 2020
Emerging Company Profile

Atlas-built Q32 debuts with $46M, tissue-targeted complement platform, BMS mAb

Atlas-incubated Q32 emerged from stealth Wednesday with a complement platform aimed at modulating the innate immune system and a lead antibody program in-licensed from BMS targeting the adaptive immune system. Formed in 2018, Q32 Bio...
BioCentury | Feb 22, 2019
Emerging Company Profile

Gyroscope complements dry AMD

Gyroscope Therapeutics Ltd.’s complement-targeting gene therapy for dry age-related macular degeneration could have an edge over competing therapies that are dosed chronically or target complement downstream of its key immune mediators. On Feb. 19, Gyroscope...
BC Innovations | Jul 24, 2018
Distillery Therapeutics

Neurology

INDICATION: Stroke Patient sample and mouse studies suggest a factor H-CR2 conjugate that inhibits C3d deposition could help treat stroke. In postmortem brain samples from three patients, deposition of C3d was higher in the perilesional...
BC Innovations | Apr 4, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: March 2018

New Therapeutic Targets and Biomarkers: March 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March 2018. Therapeutic targets are defined as any protein, gene or other...
BC Innovations | Mar 27, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Bacterial infection Chimeric antigens against N. meningitidis fHbp and N. meningitidis porA could be used to develop vaccines against serogroup B N. meningitidis infection. The antigens were generated by using a soluble N. meningitidis...
BioCentury | Oct 20, 2017
Finance

Stars align for rare AMD

Investors have backed Gemini Therapeutics Inc. with a $42.5 million series A round so the company can use the precision medicine approach that is common to cancer and rare diseases to target mutations in the...
BC Week In Review | Sep 1, 2017
Company News

Duke spinout Grid gets IP for CFH antibodies

Duke University (Durham, N.C.) granted Grid Therapeutics LLC (Durham, N.C.), formerly Cue Biologics LLC , exclusive rights to IP covering antibodies that target complement factor H (factor H; CFH) to treat cancer, and CFH-related diagnostics. Duke...
BC Extra | Aug 22, 2017
Company News

Duke spinout Grid gets IP for CFH antibodies

Duke University granted Grid Therapeutics LLC (Durham, N.C.), formerly Cue Biologics LLC, exclusive rights to IP covering antibodies that target complement factor H (factor H; CFH ) to treat cancer, and CFH-related diagnostics. Duke received a...
BC Week In Review | Aug 4, 2017
Clinical News

EC approves Pfizer's Trumenba

In May, the European Commission approved Trumenba meningococcal group B vaccine (recombinant LP2086, PF-5212366) from Pfizer Inc. (NYSE:PFE) to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals ages ≥10. The vaccine...
BC Week In Review | Mar 31, 2017
Clinical News

Trumenba regulatory update

EMA's CHMP recommended approval of an MAA from Pfizer for Trumenba meningococcal group B vaccine to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals ages ≥10. In 2014, FDA granted accelerated...
Items per page:
1 - 10 of 72